Semaglutide is a synthetic analogue of the incretin hormone glp-1 that mimics its activity in the body. It is used clinically to improve glycemic control in type 2 diabetes and to reduce cardiovascular risk. The drug works by binding to glp-1 receptors on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner. It also slows gastric emptying and reduces appetite, which can lead to weight loss. These combined effects enhance insulin sensitivity and lower blood glucose levels without causing hypoglycemia under normal conditions. The medication is administered by subcutaneous injection and provides sustained action due to its modified peptide structure.

Semaglutide is a synthetic analogue of the hormone glp-1 that mimics its activity in the body. It lowers blood glucose by enhancing insulin secretion from pancreatic beta cells and suppressing glucagon release during meals. The drug also slows gastric emptying, which contributes to reduced appetite and weight loss. These combined effects make it useful for managing type 2 diabetes and for chronic weight management in adults. Pharmacologically, Semaglutide binds to glp-1 receptors with high affinity, leading to prolonged activation of downstream signaling pathways that regulate glucose homeostasis. Its long half-life allows once-weekly dosing, providing sustained therapeutic benefit. By improving glycemic control and decreasing food intake, Semaglutide addresses both metabolic disturbances associated with obesity and diabetes.

Semaglutide can cause nausea which is most common during the first few weeks. It may lead to diarrhea or constipation affecting some patients. Headache and fatigue are also reported side effects. Some individuals experience a decrease in appetite resulting in mild weight loss. In rare cases it can cause gallbladder issues such as cholecystitis. Acute pancreatitis has been observed in a small number of users. Injection site reactions like redness or swelling can occur. Laboratory tests may show increased levels of certain enzymes but these changes are usually mild.

Semaglutide can cause a variety of side effects that are generally mild to moderate. The most commonly reported issues involve the gastrointestinal system such as nausea, vomiting, diarrhea, and constipation. Some users experience a reduced appetite which can lead to weight loss. Headache, fatigue, and mild dizziness are also observed in clinical studies. In rare cases, more serious reactions such as pancreatitis or gallbladder problems have been documented. These adverse events are usually temporary and often improve with continued use. Understanding the range of possible effects helps patients monitor their response while using the medication.